Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.

Strong, Randy

Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. [electronic resource] - Aging cell 10 2016 - 872-84 p. digital

Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural

1474-9726

10.1111/acel.12496 doi


Acarbose--pharmacology
Animals
Antioxidants--pharmacology
Drugs, Chinese Herbal--pharmacology
Estradiol--pharmacology
Fish Oils--pharmacology
Glycoside Hydrolase Inhibitors--pharmacology
Hand Strength
Longevity--drug effects
Male
Masoprocol--pharmacology
Metformin--pharmacology
Mice
NF-E2-Related Factor 2--metabolism
Rotarod Performance Test
Sirolimus--pharmacology
Survival Analysis
Ursodeoxycholic Acid--pharmacology
alpha-Glucosidases--metabolism